Antigen binding proteins
AssigneeGlaxoSmith Kline Intellectual Property Development Limited
InventorsErding Hu, Matthew Gardener
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.
Claims22
A PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO:
- 107;
- CDRH2 comprises SEQ ID NO:
- 108;
- CDRH3 comprises SEQ ID NO:
- 109;
- CDRL1 comprises SEQ ID NO:
- 113;
- CDRL2 comprises SEQ ID NO:
- 114;
- and CDRL3 comprises SEQ ID NO:
- 115.
A nucleic acid sequence that encodes a PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO:
- 107;
- CDRH2 comprises SEQ ID NO:
- 108;
- CDRH3 comprises SEQ ID NO:
- 109;
- CDRL1 comprises SEQ ID NO:
- 113;
- CDRL2 comprises SEQ ID NO:
- 114;
- and CDRL3 comprises SEQ ID NO:
- 115.
A method for the treatment of a polycystic kidney disease (PKD) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO:
- 107;
- CDRH2 comprises SEQ ID NO:
- 108;
- CDRH3 comprises SEQ ID NO:
- 109;
- CDRL1 comprises SEQ ID NO:
- 113;
- CDRL2 comprises SEQ ID NO:
- 114;
- and CDRL3 comprises SEQ ID NO:
- 115.
Dependencies are inferred from the claim text.